Literature DB >> 10604467

Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.

G N Patrick1, L Zukerberg, M Nikolic, S de la Monte, P Dikkes, L H Tsai.   

Abstract

Cyclin-dependent kinase 5 (Cdk5) is required for proper development of the mammalian central nervous system. To be activated, Cdk5 has to associate with its regulatory subunit, p35. We have found that p25, a truncated form of p35, accumulates in neurons in the brains of patients with Alzheimer's disease. This accumulation correlates with an increase in Cdk5 kinase activity. Unlike p35, p25 is not readily degraded, and binding of p25 to Cdk5 constitutively activates Cdk5, changes its cellular location and alters its substrate specificity. In vivo the p25/Cdk5 complex hyperphosphorylates tau, which reduces tau's ability to associate with microtubules. Moreover, expression of the p25/Cdk5 complex in cultured primary neurons induces cytoskeletal disruption, morphological degeneration and apoptosis. These findings indicate that cleavage of p35, followed by accumulation of p25, may be involved in the pathogenesis of cytoskeletal abnormalities and neuronal death in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604467     DOI: 10.1038/45159

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  464 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Integrin alpha(1) beta(1)-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation.

Authors:  B S Li; L Zhang; J Gu; N D Amin; H C Pant
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

3.  Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.

Authors:  Kuan-Yu Liu; Yu-Chiau Shyu; Brett A Barbaro; Yuan-Ta Lin; Yijuang Chern; Leslie Michels Thompson; Che-Kun James Shen; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

4.  Sumoylation of p35 modulates p35/cyclin-dependent kinase (Cdk) 5 complex activity.

Authors:  Anja Büchner; Petranka Krumova; Sundar Ganesan; Mathias Bähr; Katrin Eckermann; Jochen H Weishaupt
Journal:  Neuromolecular Med       Date:  2014-11-13       Impact factor: 3.843

5.  Genetic modifiers of tauopathy in Drosophila.

Authors:  Joshua M Shulman; Mel B Feany
Journal:  Genetics       Date:  2003-11       Impact factor: 4.562

Review 6.  Functional aspects of cellular microcompartmentation in the development of neurodegeneration: mutation induced aberrant protein-protein associations.

Authors:  Judit Ovádi; Ferenc Orosz; Susan Hollán
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

7.  TFP5, a peptide derived from p35, a Cdk5 neuronal activator, rescues cortical neurons from glucose toxicity.

Authors:  B K Binukumar; Ya-Li Zheng; Varsha Shukla; Niranjana D Amin; Philip Grant; Harish C Pant
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

8.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

9.  Alpha2-chimaerin, cyclin-dependent Kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse.

Authors:  Matthew Brown; Tom Jacobs; Britta Eickholt; Giovanna Ferrari; Mabel Teo; Clinton Monfries; Robert Z Qi; Thomas Leung; Louis Lim; Christine Hall
Journal:  J Neurosci       Date:  2004-10-13       Impact factor: 6.167

10.  Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease.

Authors:  Patrice D Smith; Stephen J Crocker; Vernice Jackson-Lewis; Kelly L Jordan-Sciutto; Shawn Hayley; Matthew P Mount; Michael J O'Hare; Steven Callaghan; Ruth S Slack; Serge Przedborski; Hymie Anisman; David S Park
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.